Missouri-based diagnostic provider C2N has struck a deal with diagnostic services provider Unilabs to expand access to its Precivity portfolio of Alzheimer’s blood tests in over 75 countries.

Alzpath said Monday that it has signed a licensing agreement with Beckman Coulter Diagnostics for use of the Alzpath phosphorylated-tau 217 antibody in a blood-based test for Alzheimer's disease.

A workgroup convened by the Alzheimer’s Association has published revised criteria for the diagnosis and staging of Alzheimer’s disease that are based on the biology of the disease and reflect recent advancements in Alzheimer’s research, diagnostics and treatment. The 2024 update includes an updated biomarker classification system that includes blood-based biomarkers (BBM) and a revised disease staging system.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Chinese Aging Well Association’s Alzheimer's Disease Branch has announced the launch of a special project to establish 50 new memory clinics nationwide and to conduct training in 10 regions, aiming to train approximately 1,000 professionals.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the presence or absence of amyloid pathology in individuals, which can help ensure they are able to receive appropriate care. This may include participation in clinical trials or access to approved disease-modifying therapies. If approved, the test could help rapidly broaden access to a more timely and accurate diagnosis and potentially mitigate the impact of Alzheimer’s disease on people and society.

Researchers at the Washington University in St. Louis and Lund University in Sweden have taken a step closer toward developing a blood test that could be used during an annual doctor’s office visit to help catch cases of Alzheimer’s disease.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma within just 35 minutes.

According to the Global Burden of Disease Study 2019, the number of people diagnosed with dementia is expected to almost triple by 2050.

Labcorp (LH.N) on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting disease and potentially helping patients access treatment.